Morning Brew - 🧬 Biotech breakthrough

As the world’s population ages, biotech companies are under pressure to make advances in regenerative treatments for debilitating diseases.
 
One that’s top of mind for many researchers? Osteoarthritis (OA). This disease, which erodes the protective cartilage within joints and causes severe pain, will affect 25% of the adult population by 2030.
 
There was no way to stop its progression—until Cytonics developed the first and only therapy that targets the disease at its root.

We’re not talking about a painkiller or a symptom-management strategy. It’s a straight-up disease-modifying treatment. And you have the opportunity to become a shareholder in this breakthrough today.

Cytonics has already seen proven success in regenerative medicine. They’ve commercialized an FDA-approved medical device for OA that’s successfully treated 8,000 patients. And while it was a clinical and commercial success, there is still room for improvement. 

With their next-gen OA treatment, known as CYT-108, Cytonics is taking critical steps to bring a first-of-its kind treatment to a $240b market. This therapy is even more effective for patients thanks to these advancements:

• It can be produced en masse and sold globally (read: cost-effective).
• It will be available “off the shelf” for immediate use (no lengthy doctor’s visit needed).
• It’s more likely to be covered by insurance (it’s a biopharmaceutical vs. a device).

The company is already backed by Johnson & Johnson and the National Institutes of Health. And with 22 issued and 5 pending patents, they’re making steady progress to get their game-changing biotech to the joints of 600m people (and counting) and provide a better quality of life.
 
Cytonics is currently conducting an equity crowdfunding investment round ahead of their next growth milestone, phase 1 human clinical trials, so it’s not too late to become a shareholder in this biotech breakthrough before they enter the clinic.

Cheers, 

☕️ The Brew Crew

This paid content was created with our sponsor and does not necessarily reflect the opinions or point of view of Emerging Tech Brew.

Disclosure: In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. The Company has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here.